Silexion Therapeutics Corp (SLXNW) — Insider Trading

AI-Powered SEC Filing Analysis

Latest Insider Trading Filed: 2025-12-31

Key Insights

The reporting person, Amnon Peled, acquired 661 ordinary shares and 780 stock options of Silexion Therapeutics Corp (SLXNW), indicating insider investment and alignment with shareholders.
The stock options and restricted share units granted to the director vest on the first anniversary of the grant date, suggesting long-term incentives and commitment to the company's success.
The 1-for-15 reverse share split effected by the issuer on July 29, 2025 has been properly reflected in the reported share and option amounts, providing transparency.

Want the newest filings?

This analysis covers the filing from 2025-12-31. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Insider Trading filings

Filed: 2025-12-31

Avner Lushi, a director of Silexion Therapeutics Corp, acquired 1,587 ordinary shares indirectly through the Guangzhou Sino-Israel Biotech Fund (GIBF), indicating continued investment in the company.
Lushi also holds 14,721 ordinary shares and 1,872 stock options indirectly through GIBF, suggesting his commitment to Silexion's long-term success.
The reported transactions include adjustments for a 1-for-15 reverse share split, reflecting corporate actions that may impact the company's capital structure.

Filed: 2025-12-31

The reporting person, Noy Shlomo, is a director of Silexion Therapeutics Corp (SLXN) and possesses shared voting and investment authority over securities held by Guangzhou Sino-Israel Biotech Fund (GIBF).
GIBF was granted 1,587 ordinary shares and 1,872 stock options by SLXN, which vest on the first anniversary of the grant date, subject to the reporting person's or Avner Lushi's continued service.
SLXN has undergone a series of reverse share splits, including 1-for-9 in November 2024 and 1-for-15 in July 2025, which have been reflected in the reported share and option holdings.

Filed: 2025-12-31

Insider Ruth Alon has been granted 794 RSUs by Silexion Therapeutics Corp, vesting in 1 year, indicating potential positive sentiment and alignment with long-term shareholder interests.
Silexion Therapeutics Corp has undergone a 1-for-15 reverse share split, which may impact the stock price and trading liquidity.
The reporting person has also disposed of 403 ordinary shares, which could signal a shift in their ownership position.

Filed: 2025-12-31

Dror Yosef Abramov, a director of Silexion Therapeutics Corp, acquired 794 ordinary shares of the company through a restricted stock unit grant, indicating his continued commitment to and confidence in the firm.
Abramov also holds 935 stock options to purchase ordinary shares, which have been adjusted to account for the company's recent 1-for-15 reverse share split, further aligning his interests with those of Silexion's shareholders.
The filing also discloses that Abramov previously held 295 ordinary shares, which have been adjusted downward to reflect the reverse splits, suggesting a stable insider ownership position.

Other reports for Silexion Therapeutics Corp

Current Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.